Skip to the main content

Original scientific paper

The treatment of chronic hepatitis B virus infection at the University Hospital for Infectious Diseases "Dr. Fran Mihaljević" in Zagreb in the period from 2008 to 2017

Ivan Kurelac ; University Hospital for Infectious Diseases
Davorka Dušek ; University Hospital for Infectious Diseases
Neven Papić ; University Hospital for Infectious Diseases
Jelena Mihalić ; University Hospital for Infectious Diseases
Juraj Krznarić ; University Hospital for Infectious Diseases
Snježana Židovec Lepej ; University Hospital for Infectious Diseases
Oktavija Đaković Rode ; University Hospital for Infectious Diseases
Adriana Vince ; University Hospital for Infectious Diseases


Full text: croatian pdf 611 Kb

page 3-7

downloads: 579

cite


Abstract

A total of 210 patients with chronic HBV infection and histological and biochemical activity of disease were treated at the University Hospital for Infectious Diseases "Dr. Fran Mihaljević" in Zagreb in the period from 2008 to 2017. The fibrosis stage was determined histologically and by transient elastography, and cirrhosis was found initially in 14,5 % of the patients. Although functional recovery was rare (5.5 % of cases), the suppression of viral replication, slowing down or discontinuation of fibrosis progression was achieved in most of the treated. Even fibrosis regression by one stage in Metavir scale was achieved in 16 % of patients. There was also a decrease in the frequency of development of
decompensated cirrhosis (2 patients) and hepatocellular carcinoma (2 patients) by 2 to 3 times in comparison to historical controls in nontreated patients. Patients treated with lamivudine had a high incidence of resistance development (32 % after 5 years). They continued therapy with tenofovir with good tolerability and no resistance development. HBeAg did not seem to be a significant predictor
for the severity and the course of the disease. There is also a significant
number of hematologic and other immunosuppressed patients (n = 24) receiving treatment to prevent the reactivation of latent HBV infection.

Keywords

chronic hepatitis B; treatment; nucleoside and nucleotide analogues

Hrčak ID:

216060

URI

https://hrcak.srce.hr/216060

Publication date:

22.1.2019.

Article data in other languages: croatian

Visits: 2.192 *